ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 144 filers reported holding ESPERION THERAPEUTICS INC NE in Q2 2021. The put-call ratio across all filers is 2.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,061 | -29.5% | 1,083 | 0.0% | 0.00% | – |
Q2 2023 | $1,506 | -23.0% | 1,083 | -12.0% | 0.00% | – |
Q1 2023 | $1,956 | -91.6% | 1,230 | -67.1% | 0.00% | – |
Q4 2022 | $23,294 | -44.5% | 3,739 | -40.0% | 0.00% | – |
Q3 2022 | $42,000 | +16.7% | 6,232 | +10.3% | 0.00% | – |
Q2 2022 | $36,000 | +71.4% | 5,648 | +25.7% | 0.00% | – |
Q1 2022 | $21,000 | +250.0% | 4,492 | +247.1% | 0.00% | – |
Q4 2021 | $6,000 | -89.1% | 1,294 | -71.7% | 0.00% | – |
Q3 2021 | $55,000 | -45.5% | 4,573 | -4.6% | 0.00% | – |
Q2 2021 | $101,000 | -34.0% | 4,793 | -11.9% | 0.00% | – |
Q1 2021 | $153,000 | -64.5% | 5,443 | -67.1% | 0.00% | -100.0% |
Q4 2020 | $431,000 | -47.5% | 16,566 | -25.0% | 0.00% | -50.0% |
Q3 2020 | $821,000 | +101.2% | 22,095 | +178.1% | 0.00% | +100.0% |
Q2 2020 | $408,000 | +81.3% | 7,946 | +11.3% | 0.00% | 0.0% |
Q1 2020 | $225,000 | -38.9% | 7,140 | +15.9% | 0.00% | 0.0% |
Q4 2019 | $368,000 | +231.5% | 6,159 | +103.3% | 0.00% | – |
Q3 2019 | $111,000 | -22.9% | 3,030 | -2.3% | 0.00% | – |
Q2 2019 | $144,000 | +16.1% | 3,100 | 0.0% | 0.00% | – |
Q1 2019 | $124,000 | -74.5% | 3,100 | -70.8% | 0.00% | -100.0% |
Q4 2018 | $487,000 | +4.1% | 10,600 | +0.7% | 0.00% | +100.0% |
Q3 2018 | $468,000 | -10.7% | 10,530 | -21.3% | 0.00% | -50.0% |
Q2 2018 | $524,000 | -55.7% | 13,378 | -18.2% | 0.00% | -50.0% |
Q1 2018 | $1,182,000 | +61.5% | 16,346 | +46.9% | 0.00% | +100.0% |
Q4 2017 | $732,000 | +32.1% | 11,124 | +0.7% | 0.00% | 0.0% |
Q3 2017 | $554,000 | +21.2% | 11,051 | +12.1% | 0.00% | 0.0% |
Q2 2017 | $457,000 | +32.8% | 9,856 | +1.1% | 0.00% | +100.0% |
Q1 2017 | $344,000 | +182.0% | 9,752 | 0.0% | 0.00% | – |
Q4 2016 | $122,000 | -9.6% | 9,752 | 0.0% | 0.00% | -100.0% |
Q3 2016 | $135,000 | -10.6% | 9,752 | -36.3% | 0.00% | 0.0% |
Q2 2016 | $151,000 | -41.7% | 15,320 | 0.0% | 0.00% | 0.0% |
Q1 2016 | $259,000 | +37.0% | 15,320 | +80.2% | 0.00% | 0.0% |
Q4 2015 | $189,000 | -23.8% | 8,500 | -19.0% | 0.00% | 0.0% |
Q3 2015 | $248,000 | -71.2% | 10,500 | -0.2% | 0.00% | -66.7% |
Q2 2015 | $860,000 | -11.5% | 10,522 | +0.2% | 0.00% | -25.0% |
Q1 2015 | $972,000 | +128.7% | 10,500 | 0.0% | 0.00% | +100.0% |
Q4 2014 | $425,000 | – | 10,500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 4,468,835 | $27,840,842 | 18.82% |
Ikarian Capital, LLC | 1,891,147 | $11,781,846 | 2.84% |
Altium Capital Management LP | 620,000 | $3,862,600 | 1.96% |
Ikarian Capital, LLC | 1,296,900 | $8,079,687 | 1.95% |
Parkman Healthcare Partners LLC | 822,784 | $5,125,944 | 1.36% |
Deep Track Capital, LP | 4,000,000 | $24,920,000 | 1.05% |
Monaco Asset Management SAM | 470,100 | $2,928,723 | 0.88% |
BRAIDWELL LP | 3,393,405 | $21,140,913 | 0.71% |
Telemetry Investments, L.L.C. | 71,000 | $442 | 0.70% |
Rhenman & Partners Asset Management AB | 900,000 | $5,607,000 | 0.58% |